Schilz, Laura
Kemna, Solveig
Karnouk, Carine
Böge, Kerem
Lindheimer, Nico
Walther, Lena
Mohamad, Sara
Suboh, Amani
Hasan, Alkomiet
Höhne, Edgar
Banaschewski, Tobias
Plener, Paul
Strupf, Michael
Hahn, Erik
Bajbouj, Malek http://orcid.org/0000-0002-0073-3322
Funding for this research was provided by:
g-ba (01VSF16061)
Charité - Universitätsmedizin Berlin
Article History
Received: 23 December 2021
Accepted: 21 December 2022
First Online: 12 January 2023
Declarations
:
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Alkomiet Hasan received paid speakership from Janssen, Otsuka, Lundbeck, Rovi, and Recordati and was member of advisory boards for these companies. He is the editor of the WFBSP and German guidelines for schizophrenia. He reports no COI with regard to the topic of this report. Paul Plener received speaker’s honorarium from Shire, Gerrot Lannach, Infectopharm, and Oral B. He received an advisory honorarium from Boehringer-Ingelheim. He receives royalties from Hogrefe Publishers.
: As part of the MEHIRA study, this study was conducted in accordance with the latest version of the Declaration of Helsinki and has been approved by the Ethical Committee of Charité-Universitätsmedizin Berlin (EA2/070/17).
: The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.